PolyPid to Present at the Barclays Global Healthcare Conference

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD), a biopharma company focused on enhancing surgical outcomes, will present at the Barclays Global Healthcare Conference in Miami from March 14-16, 2023. Their presentation is scheduled for March 14 at 4:35 PM Eastern Time. Investors interested in discussing with PolyPid can reach out to their Barclays representative. PolyPid's lead product, D-PLEX₁₀₀, is currently undergoing Phase 3 trials to prevent soft tissue surgical site infections. The company is also in preclinical studies with OncoPLEX targeting solid tumors, starting with glioblastoma.

PETACH TIKVA, Israel, March 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023.

Barclays Global Investor Conference:

Presentation Date:	Tuesday, March 14, 2023
Presentation Time:	4:35 PM Eastern Time

Investors interested in meeting with PolyPid during the conference should contact their Barclays representative.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts: 
PolyPid, Ltd. 
Ori Warshavsky
COO – US Operations
Tel: +1-908-376-6758

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

FAQ

When will PolyPid present at the Barclays Global Healthcare Conference?

PolyPid will present on March 14, 2023, at 4:35 PM Eastern Time.

What is the main focus of PolyPid Ltd.?

PolyPid focuses on improving surgical outcomes through advanced biopharmaceutical innovations.

What is D-PLEX100 and its significance?

D-PLEX100 is PolyPid's lead product candidate in Phase 3 trials for preventing surgical site infections.

What is the purpose of the Barclays Global Healthcare Conference?

The conference provides a platform for biopharma companies like PolyPid to present their innovations to investors.

What other products is PolyPid developing?

PolyPid is also testing OncoPLEX for the treatment of solid tumors, including glioblastoma.